<DOC>
	<DOCNO>NCT00052013</DOCNO>
	<brief_summary>The purpose study determine whether PTK787/ZK 222584 effective treat hemangioblastoma brain and/or retina patient von Hippel-Lindau disease . The study also assess safety tolerability PTK787/ZK 222584 , change marker angiogenesis ( new blood vessel growth ) .</brief_summary>
	<brief_title>Treatment Von Hippel-Lindau ( VHL ) -Related Hemangioblastoma With PTK787/ZK 222584</brief_title>
	<detailed_description />
	<mesh_term>Von Hippel-Lindau Disease</mesh_term>
	<mesh_term>Hemangioblastoma</mesh_term>
	<mesh_term>Vatalanib</mesh_term>
	<criteria>Inclusion criterion : Confirmed diagnosis VHL disease One measurable CNS hemangioblastoma , symptomatic , must refractory amenable standard therapy , asymptomatic , must least one prior neurosurgical treatment/ procedure ; and/or : least one untreatable treatmentrefractory retinal hemangioblastoma cause impaired visual function Karnofsky Performance Status &gt; =60 Life expectancy &gt; 3 month Able sign inform consent Adequate hematologic status , liver kidney function Exclusion criterion : Patients VHLrelated tumor require amenable standard treatment Severe uncontrolled concurrent illness could compromise participation study Total urinary protein 24 hour collection &gt; 500 mg Pregnant breast feeding female , adult reproductive potential use effective contraception ( hormonal method consider effective due possible decreased effectiveness secondary drug interaction PTK787 ) . Women childbearing potential must negative serum pregnancy test prior initiation treatment . Acute chronic liver disease Diagnosis HIV infection GI function may alter absorption PTK787 Patients take coumadin ( warfarin sodium ) Prior therapy ( investigational drug , chemotherapy ) within 4 week prior study entry Prior therapy ( biologic , hormonal , immunotherapy , radiation therapy , surgery ) within two week prior study entry . Patients unwilling unable comply protocol requirement Patients concurrent , non VHLrelated malignancy nonmelanoma skin cancer Patients contraindication MRI imaging</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>von Hippel-Lindau disease ,</keyword>
	<keyword>CNS ,</keyword>
	<keyword>hemangioblastoma ,</keyword>
	<keyword>retinal</keyword>
</DOC>